Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Nov;26(11):2902-2916.
doi: 10.1007/s12094-024-03736-6. Epub 2024 Sep 26.

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Teresa Alonso-Gordoa #  1 , Paula Jimenez-Fonseca #  2 , Javier Martinez-Trufero #  3 , Miguel Navarro #  4 , Ignacio Porras #  5 , Jordi Rubió-Casadevall #  6 , Marta Arregui Valles #  7 , Neus Basté #  8 , Jorge Hernando #  9 , Lara Iglesias Docampo #  10
Affiliations
Practice Guideline

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Teresa Alonso-Gordoa et al. Clin Transl Oncol. 2024 Nov.

Abstract

Thyroid cancer (TC) represents 3% of global cancer incidence. Recent changes have optimized treatment decisions based on risk assessment, molecular profiling, and imaging assessment, leading the development of targeted agents that have modified the natural history of this disease. This increasing complexity on treatment options requires careful assessment at the different stages of the disease to provide the most suitable approach from diagnosis to long-term follow-up. This guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management.

Keywords: Thyroid carcinoma; Molecular alterations; Multidisciplinary; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

TAG reports Advisory Board—Speaker from Lilly, Bayer and Astellas; Speaker from Eisai, Roche, Ipsen and Adacap; Advisory Board—Speaker—Grant from Johnson & Johnson and Advisory Board from MSD. JMT reports Speaker from Lilly, Eisai and Roche and Advisory Board—Speaker from Deciphera and Pharmamar. IPQ reports Advisory Board from Abbott; Speaker from Bayer, Eisai, Merck and Novarits and Non-financial Support from MSD. JRC reports Advisory Board from Novartis, Sanofi, Merck and Lilly and Speaker from Ipsen. MAV reports Speaker—Grant from Lilly, Roche, Pharmamar and AstraZeneca. JH reports Advisory Board and Speaker from Ipsen, Novartis, Adacap and Eisai; Speaker from Bayer and Angelini and Advisory Board and Speaker from LEO. LID reports Speaker from EISAI and Bayer; Advisory Board—Speaker from Ipsen, Lilly, Merck and BMS and Advisory Board—Speaker—Other from ROCHE and MSD. PJF, NB and MN have nothing to disclose.

Figures

Fig. 1
Fig. 1
Histological types of TC and principal molecular markers. FTC follicular thyroid carcinoma; PTC papillary thyroid carcinoma; IEFV-PTC invasive encapsulated follicular variant of papillary thyroid carcinoma; OC oncocytic carcinoma; PDTC poorly differentiated thyroid carcinoma; DHGTC differentiated high-grade thyroid carcinoma; ATC anaplastic thyroid carcinoma; del deletion; fus fusion; m mutation. (if not specified, molecular alterations are mutations)
Fig. 2
Fig. 2
Basic therapeutic itinerary of patients with localized DTC. DTC Differentiated Thyroid Carcinoma, cN0node-negative, cN + node-positive, TSH thyroid-stimulating hormone, RAI radioactive iodine
Fig. 3
Fig. 3
Treatment algorithm DTC, MTC, ATC. A Approved in patients after progression to at least one previous line of MKI in Spain, but with EMA approval in first line; B Approved in patients without alternate satisfactory options in Spain; C Off-label, indication not approved in Spain; D Only FDA approved; E EMA approved, not available in Spain; F Not recommended by EMA in RET wild type patients. G Other MKI, different from vandetanib and cabozantinib, are off-label indication not approved in Spain (i.e., lenvatinib, sunitinib, axitinib, sorafenib or pazopanib), based on small prospective trials, but may represent an option in patients with RET WT MTC. RAI-R Radioactive Iodine-Refractory, DTC Differentiated Thyroid Carcinoma, ATC Anaplastic Thyroid Carcinoma, MTC Medullary Thyroid Carcinoma, MEN2A Multiple endocrine neoplasia 2A, MEN2B Multiple endocrine neoplasia 2B, FMTC Familial medullary thyroid carcinoma, W&W Watch & Wait, PCR Polymerase chain reaction, WT Wild type, MKI Multikinase inhibitors, RLT Radioligand therapy
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. - DOI - PubMed
    1. Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer Oxf Engl. 2021;1990(157):308–47. - DOI - PMC - PubMed
    1. Las_cifras_del_Cancer_en_Espana_2023.pdf [Internet]. [cited 2024 Jan 13]. https://seom.org/images/Las_cifras_del_Cancer_en_Espana_2023.pdf
    1. Locati L, Cavalieri S, Dal Maso L, Busco S, Anderson LA, Botta L, et al. Rare thyroid malignancies in Europe: data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncol. 2020;108: 104766. - DOI - PubMed
    1. Seib CD, Sosa JA. Evolving understanding of the epidemiology of thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):23–35. - DOI - PubMed

Publication types

LinkOut - more resources